96 reports

Postpartum depression usually begins within ##–## months after delivery.

  • Depression
  • Mental Health
  • Japan
  • United States
  • Forecast

Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030 ##.

  • Depression
  • France
  • Germany
  • Italy
  • Spain

Treatment-resistant depression (TRD) - Market Insights, Epidemiology, and Market Forecast - 2030 ##.

  • Depression
  • Therapy
  • United States
  • Market Size

Postpartum depression usually begins within ##–## months after delivery.

  • Depression
  • Therapy
  • United States
  • Forecast
  • Market Size

EXECUTIVE SUMMARY ##.

  • Depression
  • Psychotic Disorder
  • APAC
  • World
  • Demand

Global Unipolar Depression Epidemiology and Patient Flow Analysis - 2017 ##.

  • Depression
  • Mental Health
  • United States
  • World
  • Forecast

Global Major Depression Epidemiology and Patient Flow Analysis - 2017 ##.

  • Depression
  • Mental Health
  • United States
  • World
  • Forecast

Global Bipolar Depression Epidemiology and Patient Flow Analysis - 2017 ##.

  • Depression
  • Mental Health
  • United States
  • World
  • Forecast
  • Top 10 countries with the most depression and anxiety
  • PSYCHOBIOTICS HOLD THE POTENTIAL TO BE USED AS AN ADJUNCT THERAPY IN PATIENTS WITH DEPRESSION

Generates ideas and inspiration for new product development. ## ## ## ## ## CONTENTS ##.

  • Depression
  • Mental Health
  • United States
  • World
  • Demand

Fetzima

8770 10000 7800

Fetzima CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Fetzima : Depression LIST OF FIGURES ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Fetzima for depression ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Fetzima for

  • Depression
  • Hormone
  • Mental Health
  • Therapy
  • United States

Europe Major Depression Epidemiology and Patient Flow Analysis - 2017 ##.

  • Depression
  • Europe
  • France
  • Germany
  • Forecast

Europe Unipolar Depression Epidemiology and Patient Flow Analysis - 2017 ##.

  • Depression
  • Europe
  • France
  • Germany
  • Forecast

Europe Bipolar Depression Epidemiology and Patient Flow Analysis - 2017 ##.

  • Depression
  • Europe
  • France
  • Germany
  • Forecast

Cymbalta

8770 10000 7800

Cymbalta CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Cymbalta : Depression ## Cymbalta : Neuropathic pain LIST OF FIGURES ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Cymbalta for depression ## Figure ##: Datamonitor Healthcare’s dru

  • Chronic Pain
  • Depression
  • European Union
  • Japan
  • United States

SAGE-217

8770 10000 7800

SAGE-## CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## SAGE-## : Depression LIST OF FIGURES ## Figure ##: Datamonitor Healthcare’s drug assessment summary of SAGE-## for depression ## Figure ##: Datamonitor Healthcare’s drug assessment summary of SAGE-##

  • Depression
  • Mental Health
  • Pathology
  • United States
  • related to depression and other mental disorders.
  • According to WHO, depression is the leading cause of disability in

Lilly' s first multibillion-dollar drug, Prozac is one of the first therapies in its class SSRI to treat clinical depression by blocking the uptake of serotonin within the human brain.

  • Depression
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Depression
  • Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder. It is also used to treat depression problems.

Johnson & Johnson is seeking to gain competitive advantage by developing nasal spray for treatment-resistant depression (which is one of the major unmet medical needs).

  • Depression
  • Allergan plc
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • LATEST CLINICAL TRIALS NEWS ON TREATMENT RESISTANT DEPRESSION
  • TREATMENT RESISTANT DEPRESSION THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2019*

TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2019* CLINICAL TRIALS BY PHASE IN E## COUNTRIES TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2019* TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E## CO

  • Clinical Trial
  • Depression
  • Pharmaceutical
  • World
  • Product Initiative

Global Depression Epidemiology and Patient Flow Analysis - 2016 ##.

  • Depression
  • Mental Health
  • United States
  • World
  • Forecast
  • MHDS - MARKET SIZE AND FORECAST 2017-2022
  • ADVANCES IN TECHNOLOGY IN TREATING MENTAL DISORDERS

AD is one of the most common types of NDDs.

  • Depression
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.

Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson and Johnson’s esketamine.

  • Depression
  • Mental Health
  • United Kingdom
  • Forecast
  • Market Size
  • TOP COMPANIES PARTICIPATING IN BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS
  • THE NUMBER OF BIPOLAR DISORDER (MANIC DEPRESSION) CLINICAL TRIALS CONDUCTED GLOBALLY, HAS INCREASED BY 36% FOR THE PERIOD 2013- 2017.

BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS,

  • Bipolar Disorder
  • Clinical Trial
  • Depression
  • Neurology
  • World

Bipolar Disorder (Manic Depression) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 ##.

  • Depression
  • Mental Health
  • Pathology
  • United States
  • World
  • BIPOLAR DISORDER (MANIC DEPRESSION)
  • Depression - Product Development Milestones

Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises ##, ## and ## molecules, respectively.

  • Depression
  • Pharmaceutical
  • Therapy
  • BIPOLAR DISORDER (MANIC DEPRESSION)
  • DEPRESSION - DORMANT PROJECTS, H2 2018

Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises ##, ## and ## molecules, respectively.

  • Depression
  • Pharmaceutical
  • Therapy
  • Clinical Trial profile. 45 Trial Title
  • Target

CLINICAL TRIALS BY END POINT STATUS POST PARTUM DEPRESSION (MATERNAL DEPRESSION / POSTNATAL DEPRESSION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT POST PARTUM DEPRESSION (MATERNAL DEPRESSION / POSTNATAL DEPRESSION) THERAPEUTICS

  • Depression
  • Therapy
  • World
  • Product Initiative
  • SAGE Therapeutics
  • TYPES OF DEPRESSION
  • CAUSES & SYMPTOMS OF DEPRESSION

Various other reasons that can trigger depression are trauma, loss of loved ones, a difficult relationship, or any stressful situation.

  • Depression
  • World
  • AstraZeneca PLC
  • Lundbeck Inc.
  • Pfizer Inc.
  • RESPIRATORY DEPRESSION (HYPOVENTILATION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS,
  • Target

RESPIRATORY DEPRESSION (HYPOVENTILATION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* RESPIRATORY DEPRESSION (HYPOVENTILATION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* RESPIRATORY DEPRESSION (HYPOVENTILATION) THERAPEUTICS C

  • Depression
  • Therapy
  • World
  • Product Initiative
  • RespireRx Pharmaceuticals Inc.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

PSYCHOTIC MAJOR DEPRESSION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* PSYCHOTIC MAJOR DEPRESSION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* PSYCHOTIC MAJOR DEPRESSION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY P

  • Depression
  • Hormone
  • Hospital
  • World
  • Product Initiative

It is a very common condition that affects ## in every ## Americans.

  • Antidepressant
  • Depression
  • Mental Health
  • Therapy
  • Market Size